DOI: 10.1097/rlu.0000000000005018 ISSN: 1536-0229
Sunitinib in Tandem With 177Lu-DOTATATE Therapy in Advanced Pancreatic Neuroendocrine Tumor
Piyush Aggarwal, Vinisha Gunasekaran, Ashwani Sood, Kushal Gupta, Chandan Krushna Das, Bhagwant Rai Mittal- Radiology, Nuclear Medicine and imaging
- General Medicine
Abstract
Various systemic treatment options are available for advanced pancreatic neuroendocrine tumors (NETs); however, individual treatment may be suboptimally effective. Sunitinib inhibits multiple kinases and signaling pathways with delay in tumor growth, whereas peptide radioreceptor therapy (PRRT) delivers targeted radiation to the tumors in pancreatic NETs. There is a dearth of literature on the combined or tandem use of these systemic treatment modalities. We present a case of 40-year-old man with advanced pancreatic NET where PRRT or sunitinib as monotherapy had a suboptimal treatment response, but the use of sunitinib in tandem with 177Lu-PRRT reinforced the response to the treatment.